Patient-derived head and neck tumor slice cultures: a versatile tool to study oncolytic virus action.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 09 2022
12 09 2022
Historique:
received:
05
11
2021
accepted:
31
08
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
15
9
2022
Statut:
epublish
Résumé
Head and neck cancer etiology and architecture is quite diverse and complex, impeding the prediction whether a patient could respond to a particular cancer immunotherapy or combination treatment. A concomitantly arising caveat is obviously the translation from pre-clinical, cell based in vitro systems as well as syngeneic murine tumor models towards the heterogeneous architecture of the human tumor ecosystems. To bridge this gap, we have established and employed a patient-derived HNSCC (head and neck squamous cell carcinoma) slice culturing system to assess immunomodulatory effects as well as permissivity and oncolytic virus (OV) action. The heterogeneous contexture of the human tumor ecosystem including tumor cells, cancer-associated fibroblasts and immune cells was preserved in our HNSCC slice culturing approach. Importantly, the immune cell compartment remained to be functional and cytotoxic T-cells could be activated by immunostimulatory antibodies. In addition, we uncovered that a high proportion of the patient-derived HNSCC slice cultures were susceptible to the OV VSV-GP. More specifically, VSV-GP infects a broad spectrum of tumor-associated lineages including epithelial and stromal cells and can induce apoptosis. In sum, this human tumor ex vivo platform might complement pre-clinical studies to eventually propel cancer immune-related drug discovery and ease the translation to the clinics.
Identifiants
pubmed: 36097280
doi: 10.1038/s41598-022-19555-0
pii: 10.1038/s41598-022-19555-0
pmc: PMC9467994
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15334Informations de copyright
© 2022. The Author(s).
Références
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Cells. 2020 Nov 23;9(11):
pubmed: 33238461
J Virol. 2010 Sep;84(17):8360-8
pubmed: 20375157
Oral Oncol. 2019 Dec;99:104460
pubmed: 31683169
Int J Cancer. 2019 Oct 1;145(7):1958-1969
pubmed: 30972741
EMBO J. 2011 Jun 21;30(15):3004-18
pubmed: 21694721
Methods Mol Biol. 2013;989:45-60
pubmed: 23483386
J Virol. 2011 Jun;85(11):5679-84
pubmed: 21450833
J Virol. 2006 Jun;80(11):5145-55
pubmed: 16698995
N Engl J Med. 2020 May 14;382(20):e57
pubmed: 32402177
Cancer Cell. 2017 Feb 13;31(2):194-207
pubmed: 28196594
Nat Cancer. 2022 Feb;3(2):219-231
pubmed: 35145327
Ann Biomed Eng. 2012 Jun;40(6):1277-88
pubmed: 21997391
Int J Med Sci. 2021 Jan 1;18(1):226-238
pubmed: 33390791
Anticancer Res. 2015 Feb;35(2):1009-16
pubmed: 25667488
Nat Med. 2021 Jul;27(7):1250-1261
pubmed: 34239134
Nat Commun. 2015 Feb 27;6:6169
pubmed: 25721094
Nature. 2011 Aug 31;477(7362):99-102
pubmed: 21886163
Front Oncol. 2018 Aug 29;8:310
pubmed: 30211111
J Virol. 2009 Sep;83(18):9102-12
pubmed: 19587033
Exp Cell Res. 2019 Oct 15;383(2):111508
pubmed: 31356815
Nat Commun. 2021 Aug 31;12(1):5195
pubmed: 34465781
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824777
Cancer Res. 2014 Jul 1;74(13):3567-78
pubmed: 24812275
Cell Death Dis. 2019 Apr 25;10(5):346
pubmed: 31024004
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Virol. 2003 May;77(9):5524-8
pubmed: 12692256
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
J Thorac Oncol. 2020 May;15(5):827-842
pubmed: 31945495
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
Anticancer Res. 2006 Mar-Apr;26(2B):1651-5
pubmed: 16619587
Clin Cancer Res. 2020 Oct 1;26(19):5153-5161
pubmed: 32669371
Oncolytic Virother. 2018 Sep 05;7:79-93
pubmed: 30234074
Int J Cancer. 2018 Oct 1;143(7):1786-1796
pubmed: 29696636
Sci Rep. 2015 Dec 09;5:17187
pubmed: 26647838
Biomedicines. 2021 Apr 13;9(4):
pubmed: 33924556
J Virol. 2019 Jan 17;93(3):
pubmed: 30404802
Cancer Res. 2018 Dec 15;78(24):6852-6865
pubmed: 30449733
Br J Cancer. 2014 Jan 21;110(2):479-88
pubmed: 24263061
Mol Immunol. 2006 Mar;43(8):1129-43
pubmed: 16139892
Viruses. 2018 Mar 02;10(3):
pubmed: 29498639
Br J Cancer. 2019 Oct;121(8):647-658
pubmed: 31530903
Ann Transl Med. 2020 Feb;8(4):114
pubmed: 32175407
Clin Cancer Res. 2017 Oct 1;23(19):5696-5702
pubmed: 28679776
Nat Commun. 2017 Jul 5;8(1):58
pubmed: 28680096
Oncoimmunology. 2019 Oct 10;8(12):e1670019
pubmed: 31741771